BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 35682739)

  • 1. The potential mechanism of gut microbiota-microbial metabolites-mitochondrial axis in progression of diabetic kidney disease.
    Ma L; Zhang L; Li J; Zhang X; Xie Y; Li X; Yang B; Yang H
    Mol Med; 2023 Oct; 29(1):148. PubMed ID: 37907885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular mechanisms of nephro-protective action of enalapril in experimental chronic renal failure].
    Ciechanowicz A
    Ann Acad Med Stetin; 1999; Suppl 52():1-93. PubMed ID: 10589103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of angiotensin II in diabetic nephropathy.
    Kennefick TM; Anderson S
    Semin Nephrol; 1997 Sep; 17(5):441-7. PubMed ID: 9316212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enalapril Diminishes the Diabetes-Induced Changes in Intestinal Morphology, Intestinal RAS and Blood SCFA Concentration in Rats.
    Jaworska K; Kopacz W; Koper M; Szudzik M; Gawryś-Kopczyńska M; Konop M; Hutsch T; Chabowski D; Ufnal M
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enalapril improves vascular and cardiac function in streptozotocin-diabetic rats.
    Crespo MJ; Dunbar DC
    Cell Mol Biol (Noisy-le-grand); 2003 Dec; 49(8):1311-8. PubMed ID: 14984003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of the renin-angiotensin system improves cerebral microcirculatory perfusion in diabetic hypertensive rats.
    Estato V; Obadia N; Carvalho-Tavares J; Freitas FS; Reis P; Castro-Faria Neto H; Lessa MA; Tibiriçá E
    Microvasc Res; 2013 May; 87():41-9. PubMed ID: 23466285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors.
    Wehbi GJ; Zimpelmann J; Carey RM; Levine DZ; Burns KD
    Am J Physiol Renal Physiol; 2001 Feb; 280(2):F254-65. PubMed ID: 11208601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
    Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enalapril decreases rat plasma concentration of TMAO, a gut bacteria-derived cardiovascular marker.
    Konop M; Radkowski M; Grochowska M; Perlejewski K; Samborowska E; Ufnal M
    Biomarkers; 2018; 23(4):380-385. PubMed ID: 29363331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota and renin-angiotensin system: a complex interplay at local and systemic levels.
    Jaworska K; Koper M; Ufnal M
    Am J Physiol Gastrointest Liver Physiol; 2021 Oct; 321(4):G355-G366. PubMed ID: 34405730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood Microbiota and Circulating Microbial Metabolites in Diabetes and Cardiovascular Disease.
    Velmurugan G; Dinakaran V; Rajendhran J; Swaminathan K
    Trends Endocrinol Metab; 2020 Nov; 31(11):835-847. PubMed ID: 33086076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Probiotic Bifidobacterium Longum Supplementation Improves Metabolic Parameters and Alters the Expression of the Renin-Angiotensin System in Obese Mice Liver.
    Machado AS; Oliveira JR; Lelis DF; de Paula AMB; Guimarães ALS; Andrade JMO; Brandi IV; Santos SHS
    Biol Res Nurs; 2021 Jan; 23(1):100-108. PubMed ID: 32700545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TMAO, a seafood-derived molecule, produces diuresis and reduces mortality in heart failure rats.
    Gawrys-Kopczynska M; Konop M; Maksymiuk K; Kraszewska K; Derzsi L; Sozanski K; Holyst R; Pilz M; Samborowska E; Dobrowolski L; Jaworska K; Mogilnicka I; Ufnal M
    Elife; 2020 Jun; 9():. PubMed ID: 32510330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbe-generated metabolite trimethylamine N-oxide and the risk of diabetes: A systematic review and dose-response meta-analysis.
    Zhuang R; Ge X; Han L; Yu P; Gong X; Meng Q; Zhang Y; Fan H; Zheng L; Liu Z; Zhou X
    Obes Rev; 2019 Jun; 20(6):883-894. PubMed ID: 30868721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products.
    Jaworska K; Huc T; Gawrys M; Onyszkiewicz M; Samborowska E; Ufnal M
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394384
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.